News Author: Sharon Worcester Publish date: November 20, 2018
WASHINGTON – Interim findings from a phase 1b/2 study indicate the combination shows promising clinical activity and ...
News Author: Sharon Worcester Publish date: November 20, 2018
WASHINGTON – Targeted next-generation sequencing may help identify SCLC patients likely to benefit from immunotherapy...
News Author: Sharon Worcester Publish date: November 19, 2018
WASHINGTON – Combined monalizumab + cetuximab is safe and promotes deep, durable responses in recurrent or metastatic...
News Author: Sharon Worcester Publish date: November 19, 2018
CHICAGO – The reversible B-cell inhibitor XmAb5871 shows promise for extending steroid benefits in SLE patients.<...
News Author: Sharon Worcester Publish date: November 16, 2018
This is the first FDA approval of a treatment for newly-diagnosed PTCL.
News Author: Sharon Worcester Publish date: November 15, 2018
There are a number of treatment options for relapsed MCL, but BTK inhibitors are particularly useful.
News Author: Sharon Worcester Publish date: November 14, 2018
WASHINGTON, D.C. – Mocetinostat/durvalumab shows activity and manageable AEs in metastatic NSCLC after progression on...
News Author: Sharon Worcester Publish date: November 14, 2018
CHICAGO – Lung CT score changes for scleroderma-related interstitial lung disease validate hematopoietic stem cel...
News Author: Sharon Worcester Publish date: November 13, 2018
CHICAGO – Predictive tests should be conducted before beginning therapy.
News Author: Sharon Worcester Publish date: November 13, 2018
CHICAGO – Molecular testing has prognostic value, but still doesn’t drive treatment under updated iwCLL guidelines.
News Author: Sharon Worcester Publish date: November 13, 2018
CHICAGO – Cytogenetic factors, minimal residual disease activity, and Philadelphia chromosome–like signature are among the features with prognostic...
News Author: Sharon Worcester Publish date: November 12, 2018
Pembrolizumab plus cisplatin-based chemoradiotherapy shows promise for locally advanced, HPV-positive head and neck squamous cell carcinoma.
News Author: Sharon Worcester Publish date: November 12, 2018
WASHINGTON – FMT shows promise for the treatment of refractory immune checkpoint inhibitor–associated colitis.
News Author: Sharon Worcester Publish date: November 7, 2018
CHICAGO – Multibiomarker disease activity score predicts RA patients’ responses to tofacitinib and tracks rituximab responses.
News Author: Sharon Worcester Publish date: November 5, 2018
CHICAGO – Etanercept alone and etanercept plus methotrexate shows greater efficacy versus methotrexate monotherap...